GENinCode

GENinCode is a clinical-stage diagnostics company developing polygenic risk assessment tests for cardiovascular disease and ovarian cancer.

Its portfolio includes CE-marked molecular tests for coronary artery disease, familial hypercholesterolaemia and thrombosis risk, alongside the ROCA test for ovarian cancer surveillance in women with BRCA gene mutations.

Tests combine molecular genotyping with clinical algorithms to generate personalised patient risk scores, supporting clinicians in preventative care and treatment decisions.